Anavex Life Sciences (AVXL): My Ideas On Their AD Remedy

Anavex Life Sciences (AVXL): My Ideas On Their AD Remedy

Adult and child hands holding encephalography brain paper cutout,autism, Stroke, Epilepsy and alzheimer awareness, seizure disorder, stroke, ADHD, world mental health day concept

ThitareeSarmkasat/iStock by way of Getty Photos

Introduction

I give a promote ranking to Anavex Life Sciences (AVXL), a CNS remedy firm primarily based in New York Metropolis. The corporate lists 18 medical or preclinical indications researched in its newest company presentation leading to a pleasant mixture of later and earlier trials in its medical pipeline. I like what the corporate is doing and would give it a maintain ranking as I’m fascinated by expecting its section 3 outcomes for AD, however I feel the corporate is at present overvalued. Due to this, I imagine that the businesses threat to reward ratio is unfavorable in comparison with different alternatives.

An essential level to contemplate is that if I gave a promote ranking to each early-stage biotech firm, particularly within the present market surroundings, I’m extra typically going to be proper than fallacious. To me, the very important factor is weeding via the multitudes of corporations to search out those who provide the finest threat to reward ratio.

Traditionally Alzheimer’s Illness (AD) has been a spot the place potential medication go to die. Massive Pharma has failed time and time over once more to develop therapies for this illness. Whereas I don’t take into account the failure of Massive Pharma a sign that it can’t be executed, I take into account it an indication of the issue of doing it.

Why I Assume it’s Overvalued

The valuation for a drug candidate earlier than it has been authorised is predicated on its likelihood for approval and the income it could usher in upon that approval, which is discounted primarily based on how distant that income is—an analytical solution to strategy a drug.

At present, Anavex 2-73 is being valued as a blockbuster drug with huge gross sales and large income. As a result of AD is such a big market with no nice remedy, any remedy that reveals potential is considered this fashion.

Contemplating the primary issue for valuing, sure, Anavex 2-73 has some optimistic information. The issue is what I simply stated within the earlier part; AD is the place potential medication go to die. Subsequently, an AD drug can have a decrease proportion likelihood of approval at any stage within the drug course of than a drug in an area the place approvals are granted extra freely, like Oncology. We see this affecting corporations throughout the board on this area, akin to INmune Bio (INMB) and Cassava Sciences (SAVA). Whereas this could grant a decrease valuation to Anavex, this isn’t the explanation I imagine it’s being overvalued.

The second cause is why I imagine that Anavex is being overvalued. Easy economics state that income is the sum of money an organization brings in. Aanavex 2-73 is in an enormous market which permits it to herald some huge cash. Anavex 2-73 shall be a brand new drug and can most certainly be priced very excessive, which as soon as once more provides it a possibility to herald some huge cash. These two elements would make its valuation be considered one of a blockbuster drug. I imagine the inventory is being valued, with solely these elements being thought-about, however an element is lacking. I imagine that Anavex 2-73 is similar to an already authorised generic drug known as donepezil. A drug that has been trusted for over ten years and has gained virtually all the out there market share. A drug that’s generic and can subsequently be offered very cheaply compared to Anavex 2-73.

Donepezil at present prices a low $13 per 30 tablets. If the drug is given two occasions a day then the yearly value is simply over $300. Regardless, of what Anavex 2-73 is priced at, a quantity which I’ve but to see, it won’t be able to be aggressive with this. The price of the model title Aricept was $540 for 30 tablets which is an affordable comparability to the place Anavex 2-73 can be priced at. Meaning donepezil would value over 40x much less.

I imagine Anavex 2-73 will wrestle to get authorised, and if it will get authorised, it should wrestle to win market share towards a less expensive, comparable drug. Subsequently I feel that the valuation of this drug must be lowered, which lowers the corporate’s valuation.

Financials

Anavex not too long ago did a funding spherical via a $50 million direct providing. Moreover, there was a submitting for a $150 million secondary providing. Per the corporate’s newest quarterly SEC submitting, the corporate has $157 million in money, balanced out by a small $9 million in liabilities. The corporate has a burn price of about $10 million per quarter. The corporate is in an excellent monetary place which is a really optimistic signal as a result of the overall biotech sector is absolutely down, making it onerous to boost capital.

The corporate at present has a powerful six trials in phase-three. Whereas section three trials are recognized to be cash-intensive, this enables means the corporate has six indications for medication near approval. If any of those are authorised, it also needs to assist the businesses money place by producing income. Institutional possession stands at 33.8%. Insider possession is comparatively low, standing at 1.7% which suggests insiders have much less stake within the share value and pursuits that are not effectively aligned with the retail investor.

Anavex’s Latest Worth Motion

Anavex Life Sciences has had a wild run over the previous 12 months. Sadly, for traders unfamiliar with biotech, their story shouldn’t be very distinctive on this area. I’ve linked the chart under; consequently, I’ll solely briefly clarify it. Previous to this previous 12 months, the inventory had constantly traded at 5 {dollars} or under. In February, June, and November, the inventory noticed large jumps up, and following these spikes in April, July, and December, the inventory noticed gradual and regular falls. Nice visualization of the catalytic nature of biotech shares.

Chart
Information by YCharts

Usually, the spikes might be defined by optimistic catalysts, and the falls might be defined by the dearth of optimistic catalysts (if the falls had been fast and sharp, I might say damaging catalysts brought about them, however none of them appear to be this). If the occasion that brought about a spike provides worth to an organization, the corporate sometimes tends to fall again and keep across the center of the start of the rise to the tip of the rise.

The primary one was not particular to Anavex; As a substitute, it was from Cassava Sciences’ first cognition announcement on February 2nd, 2021. This announcement shocked the funding and medical communities. Cassava Sciences’ Simufilam was the primary remedy to indicate cognitive enchancment over six months since donepezil initially did. In an area filled with graves, there was life.

The beginning of the second swing was on Could thirteenth, 2021 (the date of Anavex’s second-quarter outcomes report). Anavex introduced 2021 as a 12 months filled with thrilling catalysts. Then the actual propeller got here to this swing when the announcement got here out on the mechanism of motion for Anavex 2-73 on June 14th, 2022. Rapidly adopted by Anavex asserting that ANAVEX®2-73 improved main cognitive and second MDS-UPDRS in Parkinson’s over 14 weeks on June twenty eighth, 2021, and introduced that ANAVEX®2-73 considerably prevented Aβ-induced deficits in an Aβ25-35 peptide mannequin of Alzheimer’s illness in mice, with repeated each day dosing over one week on July twenty ninth, 2021. Along with these two large kickers, a optimistic announcement was made about their Rett syndrome remedy utilizing ANAVEX®2-73. To not disregard what the corporate introduced for Rett, it should be said that Rett is a uncommon illness with a small market, whereas Parkinson’s and Alzheimer’s have a number of the largest markets on the market. At its peak in June, the corporate reached a few $2 Billion market cap.

Taking a look at upcoming catalysts, Anavex goals to deliver an Alzheimer’s illness readout in its Part 2/3b trial within the second half of this 12 months. Wanting on the impending, one naturally wonders if they need to make the most of the favorable down momentum out there and make an funding. With Alzheimer’s illness, historical past has proven that any readout generally is a make or break second for a inventory. Biogen (BIIB) virtually doubled its $40 billion market cap over an approval. -On a aspect notice, with the poor market circumstances, I don’t suppose fairly the identical motion would happen, however the level stands that it’s a large deal. Moreover, an amazing choices technique for giant binary occasions in an organization is doing a straddle. A straddle is hedged however nonetheless gives the chance for nice returns.- Whereas Anavex is healthier positioned than most AD corporations, by having a big pipeline and searching into different illnesses, it could nonetheless actually really feel the sting of the punch from poor information or a rejection.

Many of the value swings had been from catalysts surrounding Anavex 2-73 utilization for AD.

ANAVEX 2-73 for Alzheimer’s Illness

Anavex’s compound 2-73 is the lead drug candidate for the corporate. There’s additionally Anavex 3-71, which is at an earlier stage of its medical progress. ANAVEX 2-73, additionally named blarcamesine, was first talked about in a 1997 patent software. Anavex purchased the rights to that patent in 2007 and has been increasing its patent portfolio ever since, however principally with technique patents.

The section 2b/3 examine of Anavex 2-73 is in 450 sufferers over 48 weeks and requires all sufferers to have an Alzheimer’s illness pathology, together with an amyloid evaluation. Main end result measures will give attention to cognition as measured by ADAS-Cog and ADCS-ADL. Two of the additional end result measures shall be CDR-SB and blood modifications in parameters of Abeta40, Abeta42, T-tau, NFL, YKL-40, neurogranin, and BACE1 focus. One factor to notice is that the corporate goes after early AD of their medical trial, which is completely different from corporations like INmune Bio and Cassava Sciences, that are going after a later stage.

Anavex 2-73 is a sigma-1 receptor agonist that the corporate believes shall be useful for the next causes:

– Information means that activation of Sigmar1 ends in restoring full housekeeping operate throughout the physique and is pivotal to restoring neural cell homeostasis and selling neuroplasticity.

– Whereas Sigmar1 expression sometimes will increase with age, this isn’t so in Alzheimer’s illness.

– Sigmar1 promotes autophagy and ends in the degradation of amyloid-beta precursor protein (NASDAQ:APP), thereby inhibiting Aβ manufacturing.

– Activation of Sigmar1 could induce cytoprotective autophagic pathways.

– Anavex 2-73 might goal a number of Alzheimer’s disease-related pathways on the similar time.

One factor is obvious, Anavex 2-73 has a good security profile. One can take a look at Cortexyme (CRTX) and see that not having a good security profile can result in a really onerous fall. However, a great security profile doesn’t assure success.

Anavex 2-73 as a Sigmar1 Agonist

There are two kinds of sigma receptors, sigma1 and sigma2. Potent sigmar1 agonists are fluvoxamine (Luvox), dextromethorphan, and Aricept (donepezil) (which is at present the usual care technique for AD). With reference to AD, donepezil was initially authorised as a cholinesterase inhibitor. Donepezil was later discovered to have an affect on the sigma1 receptor. The problem with donepezil is it would not seem to alter the underlying illness, thus, making its results solely non permanent. Moreover, evidently on the finish of its usefulness, the affected person shortly tracks again to the unique path of cognitive decline. To not low cost the drug; it provides sufferers an additional six-ish months of high quality life whose worth can’t be understated at that time in a single’s life.

In respect of the above, I discover one of many creator’s feedback to an earlier article on this web site additionally worthwhile contemplating:

[…] Nevertheless, one of many key slides the corporate presents incessantly is the PET examine displaying SIGMA1R agonism by A2-73 in mouse mind. It reaches a most of 70% at 10 mg/kg. I feel we’ve a direct comparability with Aricept from literature research that reveals Aricept achieves 93% occupancy at 10 mg/kg. So Aricept is stronger than A2-73 in the identical mannequin displaying occupancy of SIGMAR1 receptors in rodent brains. There are additionally human PET research with Aricept. It must be doable to conduct a human PET examine with A2-73 as effectively. […]

Once I initially learn Anavex’s explanations on Anavex 2-73, I got here away with the understanding that Anavex 2-73 was a novel remedy. That could be considerably deceptive to incoming traders as that isn’t solely true. As talked about beforehand, it is extremely much like donepezil. I might have somewhat seen the corporate clarify how Anavex 2-73 units itself other than donepezil. Why will this product be prescribed over an identical generic drug that has been in use for over ten years? This argument is related for all new medication however is very true on this case. The one cause I deliver it up is due to the similarities between the 2. A terrific instance of that is OxyCotin (a potent opioid) was in contrast towards placebo for sufferers with excessive ache somewhat than the plethora of opioids already available on the market. In fact, the OxyCotin will carry out a lot better than no remedy, however does that imply it performs higher than the at present out there therapies available on the market which can be cheaper and have fewer unwanted side effects? Whereas I’m knocking Anavex for this, it’s used throughout in biotech/pharma and is not at all restricted to Anavex. If the FDA permits it, it should occur.

The Earlier OLE Readout on Cognition

Anavex 2-73 has already had a readout on cognition-related measures on the open-label extension examine of its earlier trial, as introduced at CTAD 2018 and proven under:

data for OLE

Company Presentation

On an essential notice, some individuals knock open-label information as a result of it doesn’t have a placebo management. I can not solely agree with this sentiment for AD medication. Placebo has not been proven to have an impact for an prolonged interval, and due to this, I feel we are able to take this information, particularly the longer it goes, as being comparatively correct. As well as, the objective for an AD drug is to gradual cognition decline, the hope is to cease it and preserve it, and the dream is to reverse it and enhance cognition.

The prolonged trial period was 148 weeks or virtually three years. I notice a secure efficiency in ADCS-ADL within the greater focus cohort, although this efficiency first goes up after which declines, which makes the dotted inexperienced line most attention-grabbing to me on the primary slide.

As to MMSE, I notice a two-point decline in MMSE rating all through the 148 weeks examine. Beginning at month 57, I see a quicker decline. These slides from the company presentation don’t imply a ton to me. We are able to see that giving extra of the drug has a extra important impact, however what about it in comparison with comparable medication available on the market. We are going to do that ourselves under.

In 2013, an article was printed on the long-term results of cholinesterase inhibitors like donepezil, together with on each ADAS-Cog and MMSE over three years, the outcomes of that are proven under. I’ve highlighted the scores in MMSE in purple.

Cognition comparison

Development of gentle Alzheimer’s illness

One first notes an enchancment within the MMSE rating at two months (rating: 0.61), dropping a few level at 12 months (rating: -0.57). One other twelve months later, one other 1.63 factors are misplaced (rating: -2.2), and one other twelve months later, one other 0.9 factors are misplaced (rating: -3.1). There’s a complete loss in MMSE rating from a baseline of three.1 factors. Precisely as we anticipated to see, an preliminary enchancment adopted by a fast decline again into the preliminary path of the illness.

Taking a look at this chart, it could seem that Anavex 2-73 in its highest focus scores are higher than donepezil, albeit barely (-2 factors as a substitute of -3 factors). That, for me, shouldn’t be convincing sufficient for an funding. It doesn’t have a noticeable enchancment above the present medication available on the market. Most significantly, donepezil’s patent expired in November 2010, permitting the drug to be produced generically.

The Mechanism of Motion of Anavex 2-73

Authorised cholinesterase inhibitors for the remedy of Alzheimer’s Illness have a tendency to indicate good outcomes for six months after which revert to the precise state of cognitive decline of an Alzheimer’s affected person, whatever the measurement check (as seen by the MMSE and ADAS-Cog scores on the chart above).

I notice a similar-looking curve when wanting on the outcomes produced by Anavex. A decline follows an enchancment. The same chart makes me anxious that the mechanism of motion of Anavex 2-73 in Alzheimer’s illness is probably not a lot completely different from that of acetylcholinesterase inhibitors. I wrote earlier about how donepezil impacts the sigma1 receptor, making me suppose that Anavex 2-73 does the identical factor.

I have to say that the literature is especially scarce on Anavex 2-73’s mechanism of motion. Anavex itself made a press launch earlier this 12 months on the mechanism of motion of Anavex 2-73, relating to an article that impartial authors had printed. Nonetheless, I discovered that article and the abstract Anavex made in its press launch somewhat elucidating the potential of Anavex’s drug candidates.

Wanting additional, I discovered no information on the impact of Anavex 2-73 on continual neuroinflammation in any of Anavex’s paperwork and discover that significantly worrying for the next cause. As of as we speak, there are 4 hallmarks of Alzheimer’s: amyloid-beta, tau, neuroinflammation, and cognition. Biomarkers can not assess cognition. They will assess the opposite three. The mere removing of amyloid-beta and tau has up to now been proven to have little impact on cognition. Consequently, I perceive why Anavex doesn’t give attention to these; sufficient drug failures have come alongside to warrant this resolution. Nevertheless, decreasing neuroinflammation could result in a change within the ranges of activation of microglia and, subsequently, neuroprotection. There’s ample literature in that regard, a lot in order that neuroinflammation and the position of microglia as a part of the mind’s immune system are talked about in any latest literature for neurodegenerative illnesses.

There are a lot of methods to measure neuroinflammation and/or the involvement of microglia. However ignoring what a drug candidate does relating to neuroinflammation and microglial exercise is ignoring the broader state of the science and literature. To really feel comfy as an investor, I would love a readout on that information, particularly contemplating we’re in a section three trial. There was ample likelihood to take action already.

I did learn that Anavex claims that:

SIGMAR1 has emerged as one of many distinguished targets in treating neurodegeneration. It’s concerned in […] suppressing neuroinflammation and ameliorating Aβ toxicity9. […] SIGMAR1 agonists, together with ANAVEX®2-73 and ANAVEX®3-71 have been reported to dam poisonous Aβ, tau and neuroinflammation11.

I’ve seemed on the referenced literature below footnotes 9 and 11 however have didn’t learn the affirmation that Sigmar1 antagonism reduces neuroinflammation. I’ve executed some extra analysis, the outcomes of which aren’t so simple.

I did learn this quote within the first article referenced below footnote 9, which for me is indicative of a set of hypotheses – discover using the phrase ‘could’ – of the workings of the sigma-1 receptor, and completely different pathways which can be poorly understood, each with Anavex 2-73 as with donepezil:

The mechanisms of sigma-1 receptor-mediated neuroprotective and anti-amnestic results aren’t absolutely understood, however could embrace regulation of calcium, modulation of Bcl-2 and caspase degree, and attenuation of oxidative stress. Sigma-1 receptor activation might also restrict the propagation of downstream pathological cascades, as a result of the combined sigma-1 receptor and muscarinic agonist ANAVEX 2-73 prevented tau hyperphosphorylation and Aβ1-42 manufacturing in Aβ25-35-treated mice by altering glycogen synthase kinase 3β (GSK3β) exercise ). Moreover, sigma agonists could have anti-inflammatory results; afobazole, as an example, diminished microglial activation whereas concomitantly reducing Bax and caspase-3 ranges and rising survival in cultured cells uncovered to Aβ25-35.

Whereas preclinical proof means that sigma-1 receptor agonists could assist deal with AD, no selective sigma-1 agonist is on the market for medical use. Two presently authorised medication, donepezil, and memantine, each act on sigma-1 receptors along with their different main pharmacological targets, however whether or not any of their therapeutic results are mediated by sigma-1 receptor exercise has not been decided.

Lastly, I did see that the readout of the section 2b/3 outcomes will embrace NFL, YKL-40, and neurogranin. I discover these are three blood parameters attention-grabbing, and I shall be watching for his or her reported numbers.

Approval in Alzheimer’s

One ought to take into account the bar for approval in Alzheimer’s illness as effectively. Opposite to another circumstances (akin to most cancers), the bar for approval in AD has at all times been very excessive. One ought to not less than be capable to present a stabilization of cognition, and whereas this will likely have been the case in ADCS-ADL within the OLE examine, this wasn’t the case within the MMSE measurements. This bar hasn’t modified with the Biogen resolution on Aduhelm in my eyes; Biogen’s Aduhelm has acquired accelerated approval as a result of Aduhelm was capable of take away a trademark of Alzheimer’s, amyloid, which is a surrogate endpoint. Closing approval of aduhelm continues to be conditional upon precise results on cognition in a section 4 confirmatory trial, which I query if that approval shall be granted (my questioning additionally appears to be backed by the market, which took away all of Biogen’s market cap features and a few from their approval). Plus, the FDA should still search to withdraw the accelerated approval profit at any time:

FDA will proceed to observe Aduhelm because it reaches the market and in the end the affected person’s bedside. Moreover, FDA is requiring Biogen to conduct a post-approval medical trial to confirm the drug’s medical profit. If the drug doesn’t work as meant, we are able to take steps to take away it from the market. However hopefully, we are going to see additional proof of profit within the medical trial and as better numbers of individuals obtain Aduhelm. As an company, we will even proceed to work to foster drug growth for this catastrophic illness.

For aduhelm, the FDA’s advisory board suggested towards the preliminary approval. Three members of that very same prestigious board resigned over the drug’s approval. There was a complete whirlwind of different preliminary controversies at approval. Contemplating all of that, I don’t suppose the prospects look nice for aduhelm. Moreover, following a draft resolution, Medicare could not cowl aduhelm until given to sufferers being a part of a trial. This resulted in Biogen boosting its confirmatory trial and slicing the unique extremely excessive value in half.

In my eyes, the most effective hope for the survival of aduhelm can be the approval of one other drug that helps the remedy of Alzheimer’s illness in one other manner and/or via one other pathway. I imagine that eradicating amyloid could in the end be useful, simply not as a standalone remedy.

Anavex doesn’t deliver comforting outcomes on some other biomarker or surrogate endpoints of AD. It has had the time to get these outcomes at this level; it doesn’t take away amyloid, nor tau, nor does it deliver down neuroinflammation, insofar as I’m conscious. Each Cassava Sciences and INmune Bio have much better outcomes at this degree, even when one would ignore open-label information on cognition within the case of Cassava Sciences (which is in the identical boat as Anavex) or information on neurodegeneration / synaptic enchancment within the case of INmune Bio.

To conclude, the choice of accelerated approval for Anavex 2-73 is out in any case, and last approval primarily based on a optimistic cognition readout doesn’t look very promising.

Lastly, I didn’t discover how many individuals had been nonetheless left within the OLE examine. Granted, that is extra of a private gripe, nevertheless it should not be so onerous to search out the information I’m fascinated by. Why is that this information not simply accessible? Moreover, I see Anavex had some testimonials of sufferers on the drug some years in the past that one can nonetheless discover in an earlier article on this web site. Nonetheless, I’ve not seen any updates on these sufferers. Nevertheless inviting they could look, one also needs to take these testimonials with a grain of salt. The enhancements to the affected person are unimaginable for the affected person and people of their lives. Nevertheless, as traders, our job is to chop via the smoke screens and strategy the choice analytically, not emotionally. The corporate screens them, and they’re, in essence, propaganda. The corporate shouldn’t be going to indicate you a damaging testimonial. For that cause, I don’t put a lot weight into testimonials from the corporate, however when the corporate decides to advertise testimonials, I really feel that they need to be adopted up.

To summarize, there’s a generic drug available on the market that has comparable results and does, in essence, the identical factor. Even when Anavex 2-73 will get authorised, donepezil shall be less expensive as a result of it’s generic, forcing Anaxex to drop its value and never make as a lot cash from it or resulting in the drug having bother successful market share. I additionally suppose it will have an effect on the probabilities of the drug being authorised because the FDA could drive it to show it’s higher than donepezil for approval or, on the very least, a cause it must be authorised aside from for the corporate to generate profits.

The Optimistic Readout in Parkinson’s Illness

2021 noticed a optimistic readout in Parkinson’s on June twenty eighth, 2021, as Anavex introduced that ANAVEX 2-73 improved main cognitive and second MDS-UPDRS in that illness. I quote the significantly boasting press launch.

Therapy with ANAVEX®2-73 not solely slows the development of motor and non-motor signs in reasonably superior sufferers with Parkinson’s. ANAVEX®2-73 additionally resulted in clinically significant enhancements as measured by the worldwide composite rating of Parkinson’s illness symptom severity, MDS-UPDRS Complete rating on prime of ordinary of care together with dopaminergic remedy, levodopa and different anti-PD medicines after 14 weeks of remedy, suggesting ANAVEX®2-73’s international functionality of slowing and reversing signs that progress in Parkinson’s illness, an pressing unmet medical want. […]

ANAVEX 2-73 excessive dose demonstrated statistically important enhancements in comparison with placebo (ITT inhabitants) for MDS-UPDRS Complete rating (p = 0.034). From baseline to finish of the trial at 14 weeks, MDS-UPDRS Complete rating improved by -10.98 factors within the ANAVEX 2-73 excessive dose group and worsened by 3.53 factors within the placebo group. An adjusted imply distinction of -14.51 factors (p = 0.034) corresponded to a relative enchancment of 18.9% over 14 weeks.

The present empirically established cutoff rating of -7.1 for detecting significant medical change was exceeded. For reference, the noticed worsening of MDS-UPDRS Complete rating in sufferers with Parkinson’s illness within the literature is estimated to be within the vary of three.99 to 7.45 factors per 12 months.

The above readout for Parkinson’s illness was on a 14-week remedy interval. In that very same interval, one notes that in each the above readouts within the AD open-label extension examine, Anavex 2-73 confirmed optimistic outcomes. That makes me surprise if these outcomes might be maintained for a considerably longer interval.

I take a look at these ends in Parkinson’s illness is promising. Be that as it might, the market is an environment friendly place. These outcomes are already priced in. These outcomes don’t change the overvaluation I see in Anavex 2-73 for AD.

Dangers

As at all times, investing in a biotech firm comes with dangers. For one factor, the overall market is in an abysmal state. Second, biotech shares are extremely risky. Anavex inventory shortly strikes up or down 5% in a day. As a result of I wrote a bear case, the largest risk to my thesis is that the corporate can show that Anavex 2-73 is sufficient enchancment upon donepezil to warrant the premium paid for Anavex 2-73.

Whereas optimistic readouts on its AD and/or Parkinson’s trials will shoot up the inventory value, it could additionally change the valuation equation I’m at present utilizing as a result of the drug can be nearer to approval.

Conclusion

My argument is that I don’t imagine Anavex’s Alzheimer’s drug has the identical worth as others do. Because of this, the inventory would not seem like a great buy at its present value. I imagine there are higher funding alternatives out there as a complete and biotech particularly. One could argue that the corporate is a “higher worth” now than beforehand. Whereas that is true compared to itself, it’s not legitimate compared to the remainder of biotech as a result of, as I wrote about in my article on (XBI) commenting on the biotech sector, the entire biotech market has been hit. Subsequently, any low cost for this inventory compared to its earlier value will greater than seemingly be current in some other biotech inventory one is taking a look at.

After wanting into Anavex 2-73, I’m staying on the sideline. Except the present valuation noticeably decreases in comparison with different alternatives, or I can see why Anavex 2-73 is a greater sufficient drug than donezepil to justify the numerous premium that may most certainly be paid for it, I give this inventory a promote ranking. If my questions are answered and Anavex knocks it out of the park with their information, I’m more than pleased to take a look at the corporate and probably open a place. Nevertheless, historical past is towards any firm on this area.